The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and are eligible for the national R21/Matrix-M vaccination program will be enrolled. Malaria infection will be determined by blood smear microscopy. Children with a positive microscopy result will be classified as cases and children with a negative result as controls. Vaccination history, including the number and timing of doses, will be obtained primarily from vaccination cards or other written records. Vaccine effectiveness will be estimated by comparing the odds of vaccination among cases and controls.
Inclusion Criteria:
Exclusion Criteria:
Eligible children with suspected malaria whose enrollment blood smear microscopy result is positive for P. falciparum infection
Eligible children with suspected malaria whose enrollment blood smear microscopy result is negative for P. falciparum infection
Boromo, Boucle Mouhoun, Burkina Faso
tintoh@crun.bf+226 25 40 92 12
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
tintoh@crun.bf+226 25 40 92 12
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
tintoh@crun.bf+226 25 40 92 12
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
tintoh@crun.bf+226 25 40 92 12
Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
tintoh@crun.bf+226 25 40 92 12
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)